A Six-LncRNA Expression Signature Associated with Prognosis of Colorectal Cancer Patients
- PMID: 30396175
- DOI: 10.1159/000494868
A Six-LncRNA Expression Signature Associated with Prognosis of Colorectal Cancer Patients
Abstract
Background/aims: Colorectal cancer (CRC) is one of the most common malignant tumor with high migration and invasion capacity. Long non-coding RNAs (lncRNAs) have been identified to influence multiple cancers progression through competitively binding microRNAs (miRNAs). In this study, we proposed to develop a lncRNA-based signature for CRC survival outcomes.
Methods: LncRNA expression profiles of CRC patients were extracted from the Gene Expression Omnibus (GEO) data sets GSE38832 (training set) and GSE29621 (testing set) . Associations between lncRNA expression and CRC disease free survival (DFS) were evaluated through univariate Cox regression analysis, and prognosis signature constructed by combination of weighted lncRNA expression values were obtained through multivariate Cox regression analysis. Robustness of the prognosis signature was evaluated through receiver operating characteristics analysis in the testing set.
Results: A weighted prognosis signature of six lncRNAs, including LINC01583, LINC00276, LUNAR1, DKFZp434J0226, SFTA1P and OGFOD3, was yielded from multivariate Cox regression analysis. Samples with significantly different DFS dislayed distinct signatures, indicating considerable predictory accuracy of this expression signature.
Conclusion: Robustness of the prognosis signature was evaluated in the testing set through Kaplan-Meier and receiver operating characteristics (ROC) analysis. Furthermore, functional enrichment analysis of lncRNAs suggested significant enrichment of cancer related pathways. Our results revealed the promise of lncRNAs as prognostic biomarkers.
Keywords: Colorectal cancer; GEO; LncRNA; Prognosis.
© 2018 The Author(s). Published by S. Karger AG, Basel.
Similar articles
-
Discovery of a novel six-long non-coding RNA signature predicting survival of colorectal cancer patients.J Cell Biochem. 2018 Apr;119(4):3574-3585. doi: 10.1002/jcb.26548. Epub 2018 Jan 15. J Cell Biochem. 2018. PMID: 29227531
-
Identification and Validation of Six Autophagy-related Long Non-coding RNAs as Prognostic Signature in Colorectal Cancer.Int J Med Sci. 2021 Jan 1;18(1):88-98. doi: 10.7150/ijms.49449. eCollection 2021. Int J Med Sci. 2021. PMID: 33390777 Free PMC article.
-
Exploring prognostic potential of long noncoding RNAs in colorectal cancer based on a competing endogenous RNA network.World J Gastroenterol. 2020 Mar 28;26(12):1298-1316. doi: 10.3748/wjg.v26.i12.1298. World J Gastroenterol. 2020. PMID: 32256018 Free PMC article.
-
Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.J Exp Clin Cancer Res. 2015 Sep 11;34(1):102. doi: 10.1186/s13046-015-0219-5. J Exp Clin Cancer Res. 2015. PMID: 26362431 Free PMC article.
-
LncRNA signature in colorectal cancer.Pathol Res Pract. 2021 Jun;222:153432. doi: 10.1016/j.prp.2021.153432. Epub 2021 Apr 7. Pathol Res Pract. 2021. PMID: 33857856 Review.
Cited by
-
USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma.Front Genet. 2021 Nov 2;12:762160. doi: 10.3389/fgene.2021.762160. eCollection 2021. Front Genet. 2021. PMID: 34795697 Free PMC article.
-
Construction and analysis of an aberrant lncRNA-miRNA-mRNA network associated with papillary thyroid cancer.Medicine (Baltimore). 2020 Nov 6;99(45):e22705. doi: 10.1097/MD.0000000000022705. Medicine (Baltimore). 2020. PMID: 33157921 Free PMC article.
-
Identification of key lncRNAs in age-related macular degeneration through integrated bioinformatics and experimental validation.Aging (Albany NY). 2024 Mar 14;16(6):5435-5451. doi: 10.18632/aging.205656. Epub 2024 Mar 14. Aging (Albany NY). 2024. PMID: 38484366 Free PMC article.
-
Identification of a Prognostic Colorectal Cancer Model Including LncRNA FOXP4-AS1 and LncRNA BBOX1-AS1 Based on Bioinformatics Analysis.Cancer Biother Radiopharm. 2022 Dec;37(10):893-906. doi: 10.1089/cbr.2020.4242. Epub 2021 Jan 21. Cancer Biother Radiopharm. 2022. PMID: 33481661 Free PMC article.
-
Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer.Pathol Oncol Res. 2022 Aug 11;28:1610536. doi: 10.3389/pore.2022.1610536. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36032659 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical